Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00086801 · ClinicalTrials.gov registry record · Phase 2
Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage I or Stage II Hodgkin's Lymphoma
A Phase 2 study of Lymphoma, sponsored by Alliance for Clinical Trials in Oncology.
- Completed
- Registry status
- Phase 2
- Development phase
- 104
- Enrollment target
- 20
- Study locations
NCT00086801: Completed Phase 2 study of Lymphoma, sponsored by Alliance for Clinical Trials in Oncology.
NCT00086801 is a Phase 2 study of Lymphoma that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 104 participants, below the 483-participant average among 299 other Lymphoma trials with a reported enrollment target (78% lower). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00086801, a Phase 2 study of Lymphoma, has completed, sponsored by Alliance for Clinical Trials in Oncology.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 104 participants
- Enrollment target
- 20
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy, such as doxorubicin, vinblastine, and gemcitabine, work in different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: This phase II trial is studying how well combination chemotherapy works in treating patients with newly diagnosed stage I or stage II Hodgkin's lymphoma.
Conditions Studied
Interventions
- PROCEDURE CT scan
- DRUG vinblastine
- DRUG doxorubicin hydrochloride
- DRUG gemcitabine hydrochloride
- PROCEDURE fludeoxyglucose F 18 positron-emission tomography (PET) scan
Study Locations (20)
Indiana
- Elkhart General Hospital - Elkhart
- Howard Community Hospital at Howard Regional Health System - Kokomo
- Center for Cancer Therapy at LaPorte Hospital and Health Services - La Porte
- CCOP - Northern Indiana CR Consortium - South Bend
- Memorial Hospital of South Bend - South Bend
- Saint Joseph Regional Medical Center - South Bend
Iowa
- Iowa Blood and Cancer Care - Cedar Rapids
- St. Luke's Hospital - Cedar Rapids
- Mercy Regional Cancer Center at Mercy Medical Center - Cedar Rapids
Massachusetts
- Massachusetts General Hospital Cancer Center - Boston
- Dana-Farber/Brigham and Women's Cancer Center - Boston
- Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute - Boston
Delaware
- Beebe Medical Center - Lewes
- CCOP - Christiana Care Health Services - Newark
District of Columbia
- Lombardi Comprehensive Cancer Center at Georgetown University Medical Center - Washington D.C.
- Walter Reed Army Medical Center - Washington D.C.
Maryland
- Greenebaum Cancer Center at University of Maryland Medical Center - Baltimore
- Union Hospital Cancer Center at Union Hospital - Elkton MD
California
- UCSF Comprehensive Cancer Center - San Francisco
Illinois
- University of Chicago Cancer Research Center - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 104 participants |
| Start Date | 2004-05 |
| Est. Completion | 2011-05 |
| Phase | Phase 2 |
What the finished NCT00086801 record still lists
NCT00086801 is an interventional study that assigns participants to a tested intervention. The registered 104 participants enrollment target is mid-sized for trials with a published cap, below the 483-participant average among 299 other Lymphoma trials with a reported enrollment target (78% lower).
The record links to 1 condition, with Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which CT scan is the first listed.
NCT00086801 names 20 study sites across 8 states, led by Indiana, Iowa, Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00086801 about?
NCT00086801 is a clinical study titled "Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage I or Stage II Hodgkin's Lymphoma". RATIONALE: Drugs used in chemotherapy, such as doxorubicin, vinblastine, and gemcitabine, work in different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. PURPOSE: This phase II trial is studying how well combination che...
What is the current status of trial NCT00086801?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 104 participants. The study started on 2004-05. Estimated completion is 2011-05.
What conditions does trial NCT00086801 study?
This clinical trial studies the following conditions: Lymphoma.
What interventions are being tested in trial NCT00086801?
The interventions under investigation include: CT scan (PROCEDURE), vinblastine (DRUG), doxorubicin hydrochloride (DRUG), gemcitabine hydrochloride (DRUG), fludeoxyglucose F 18 positron-emission tomography (PET) scan (PROCEDURE).
Who is sponsoring clinical trial NCT00086801?
This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00086801 being conducted?
This trial has 20 study locations across California, Delaware, District of Columbia, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00086801's enrollment target sits among peer trials
104 77th of 299 higher than 221 of 299 other Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
RECRUITING · Phase 2
-
A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy
RECRUITING · Phase 2
-
Odronextamab in Low Tumor Volume Advanced FL
RECRUITING · Phase 2
-
A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular Lymphoma
RECRUITING · Phase 2
-
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
RECRUITING · Phase 2
-
Pilot Trial of Fecal Microbiota Transplantation for Lymphoma Patients Receiving Axicabtagene Ciloleucel Therapy.
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03403686 · 104 participants
Liver X Receptor (LXR) as a Novel Therapeutic Target in Diabetic Retinopathy (DR)
- NCT04228367 · 104 participants · NA
JuggerStitch Post Market Clinical Follow-up Study
- NCT04268849 · 104 participants · Phase 3
Trial of IV vs Oral Iron Treatment of Iron Deficiency Anemia in the Post-Operative Bariatric Surgical Patient
- NCT04390724 · 104 participants
Optimizing Y90 Therapy for Radiation Lobectomy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia